top of page

®

Foveal LLP Independent Investment Research Foveal Research

prescient biotech & pharma global equity research

Independent Investment Research

Search

Unravelling the MYSTICal

Oct 13, 2016

1 min read

Astra's underappreciated oncology pipeline stalking the market

We initiate on AstraZeneca with an overweight rating and a Target Price of £56, finding that Astra’s oncology pipeline is underappreciated

Login in to download pdf

Comments

Focus Research

BMY: Does the IPF Phase 3 Win Change the Investment Case?

BMY: Does the IPF Phase 3 Win Change the Investment Case?

BMY: Does the IPF Phase 3 Win Change the Investment Case?

OPUS-1: what matters beyond management’s PCV base case

OPUS-1: what matters beyond management’s PCV base case

OPUS-1: what matters beyond management’s PCV base case

NOVN/AMGN/IONS: LP(a) after the pelacarsen failure

Multiple Myeloma

Multiple Myeloma

BMY: Is the Market Underpricing Zenbexus?

Multiple Myeloma

Multiple Myeloma

Ahead of ASCO: is mezigdomide still being framed too conservatively?

Positive LidERA? Hidden risks beneath the SERD surface

Positive LidERA? Hidden risks beneath the SERD surface

Positive LidERA? Hidden risks beneath the SERD surface

Alzheimer's

Alzheimer's

Cobenfy in Alzheimer’s: is consensus too dismissive?

sHTG

sHTG

ARWR/IONS: sHTG and pancreatitis-Does SHASTA signal or CORE command?

IgA Nephropathy: VRTX/VERA/NVS/Otsuka: RAINIER Asymmetric Risk Into the upcoming 2026 phase III

IgA Nephropathy: VRTX/VERA/NVS/Otsuka: RAINIER Asymmetric Risk Into the upcoming 2026 phase III

IgA Nephropathy: VRTX/VERA/NVS/Otsuka: RAINIER Asymmetric Risk Into the upcoming 2026 phase III

BMY/BAYN/JNJ Factor XI: Is the Market Mispricing Milvexian? Stroke valuation leverage underappreciated. AF optionality overlooked

BMY/BAYN/JNJ Factor XI: Is the Market Mispricing Milvexian? Stroke valuation leverage underappreciated. AF optionality overlooked

BMY/BAYN/JNJ Factor XI: Is the Market Mispricing Milvexian? Stroke valuation leverage underappreciated. AF optionality overlooked

Recent Reseacrh

BMY: Does the IPF Phase 3 Win Change the Investment Case?

BMY: Does the IPF Phase 3 Win Change the Investment Case?

BMY: Does the IPF Phase 3 Win Change the Investment Case?

OPUS-1: what matters beyond management’s PCV base case

NOVN/AMGN/IONS: LP(a) after the pelacarsen failure

Multiple Myeloma

Multiple Myeloma

BMY: Is the Market Underpricing Zenbexus?

Multiple Myeloma

Multiple Myeloma

Ahead of ASCO: is mezigdomide still being framed too conservatively?

Positive LidERA? Hidden risks beneath the SERD surface

Positive LidERA? Hidden risks beneath the SERD surface

Positive LidERA? Hidden risks beneath the SERD surface

Alzheimer's

Alzheimer's

Cobenfy in Alzheimer’s: is consensus too dismissive?

sHTG

sHTG

ARWR/IONS: sHTG and pancreatitis-Does SHASTA signal or CORE command?

IgA Nephropathy: VRTX/VERA/NVS/Otsuka: RAINIER Asymmetric Risk Into the upcoming 2026 phase III

IgA Nephropathy: VRTX/VERA/NVS/Otsuka: RAINIER Asymmetric Risk Into the upcoming 2026 phase III

IgA Nephropathy: VRTX/VERA/NVS/Otsuka: RAINIER Asymmetric Risk Into the upcoming 2026 phase III

BMY/BAYN/JNJ Factor XI: Is the Market Mispricing Milvexian? Stroke valuation leverage underappreciated. AF optionality overlooked

BMY/BAYN/JNJ Factor XI: Is the Market Mispricing Milvexian? Stroke valuation leverage underappreciated. AF optionality overlooked

BMY/BAYN/JNJ Factor XI: Is the Market Mispricing Milvexian? Stroke valuation leverage underappreciated. AF optionality overlooked

Archive

Search By Tags

Follow Us on:

Bloomberg: FOVL <go>

ThomsonReuters

FactSet

Captial IQ

bottom of page